Royce & Associates LP Vanda Pharmaceuticals Inc. Transaction History

Royce & Associates LP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 23, 2023	BUY	$6.87 - $10.96 $88,080 - $140,518	12,821 New	12,821 $94,000
Q4 2022 Feb 13, 2023	SELL	$6.87 - $10.96 $70,994 - $113,260	-10,334 Reduced 44.63%	12,821 $95,000
Q3 2022 Nov 03, 2022	SELL	$9.44 - $11.76 $499,451 - $622,198	-52,908 Reduced 69.56%	23,155 $229,000
Q2 2022 Aug 04, 2022	SELL	$9.31 - $11.84 $1.52 Million - $1.94 Million	-163,564 Reduced 68.26%	76,063 $829,000
Q1 2022 May 05, 2022	BUY	$10.84 - $16.55 $1.29 Million - $1.97 Million	119,329 Added 99.19%	239,627 $2.71 Million
Q4 2021 Feb 07, 2022	SELL	$15.69 - $21.14 $80,317 - $108,215	-5,119 Reduced 4.08%	120,298 $1.89 Million
Q3 2021 Nov 10, 2021	SELL	$15.35 - $21.27 $122,707 - $170,032	-7,994 Reduced 5.99%	125,417 $2.15 Million
Q2 2021 Aug 06, 2021	SELL	$15.71 - $21.51 $52,581 - $71,993	-3,347 Reduced 2.45%	133,411 $2.87 Million
Q1 2021 May 10, 2021	BUY	$13.42 - $20.28 $45,211 - $68,323	3,369 Added 2.53%	136,758 $2.05 Million
Q4 2020 Feb 08, 2021	BUY	$9.77 - $13.81 $623,726 - $881,644	63,841 Added 91.79%	133,389 $1.75 Million
Q3 2020 Nov 12, 2020	BUY	$9.32 - $12.02 $329,387 - $424,810	35,342 Added 103.32%	69,548 $672,000
Q2 2020 Aug 07, 2020	BUY	$9.66 - $12.02 $57,177 - $71,146	5,919 Added 20.92%	34,206 $391,000
Q1 2020 May 12, 2020	BUY	$7.5 - $16.8 $6,060 - $13,574	808 Added 2.94%	28,287 $293,000
Q4 2019 Feb 06, 2020	BUY	$12.38 - $17.47 $163,329 - $230,481	13,193 Added 92.35%	27,479 $451,000
Q3 2019 Nov 13, 2019	BUY	$12.27 - $15.79 $175,289 - $225,575	14,286 New	14,286 $190,000

156

44.7M

167K

33.6K

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $271M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.